Search Result

Results for "

cognitive+deficits

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) 5-HT Receptor (6) Adrenergic Receptor (2) Akt (3) Amyloid-β (6) Apoptosis (2) Autophagy (2) Bacterial (1) Calcium Channel (3) Caspase (1) CDK (1) Cholinesterase (ChE) (4) COX (1) Cytochrome P450 (1) Dopamine Receptor (3) Endogenous Metabolite (2) Epigenetic Reader Domain (1) ERK (1) FOXO (2) GPR139 (1) GSK-3 (3) HDAC (3) Histamine Receptor (1) Interleukin Related (3) mAChR (5) Mitochondrial Metabolism (1) MMP (1) Monoamine Oxidase (1) mTOR (1) nAChR (8) NF-κB (4) NO Synthase (1) NOD-like Receptor (NLR) (1) p38 MAPK (1) Phosphatase (3) Phosphodiesterase (PDE) (2) PKA (1) Potassium Channel (2) Reactive Oxygen Species (ROS) (4) Reference Standards (3) Ribosomal S6 Kinase (RSK) (1) SOD (1) STAT (1) Tau Protein (5) TNF Receptor (2) α-synuclein (1) γ-secretase (2)
By Research Areas:	Cancer (7) Inflammation/Immunology (7) Metabolic Disease (7) Neurological Disease (45)

By Targets:

17β-HSD (1)

5-HT Receptor (6)

Adrenergic Receptor (2)

Akt (3)

Amyloid-β (6)

Apoptosis (2)

Autophagy (2)

Bacterial (1)

Calcium Channel (3)

Caspase (1)

CDK (1)

Cholinesterase (ChE) (4)

COX (1)

Cytochrome P450 (1)

Dopamine Receptor (3)

Endogenous Metabolite (2)

Epigenetic Reader Domain (1)

ERK (1)

FOXO (2)

GPR139 (1)

GSK-3 (3)

HDAC (3)

Histamine Receptor (1)

Interleukin Related (3)

mAChR (5)

Mitochondrial Metabolism (1)

MMP (1)

Monoamine Oxidase (1)

mTOR (1)

nAChR (8)

NF-κB (4)

NO Synthase (1)

NOD-like Receptor (NLR) (1)

p38 MAPK (1)

Phosphatase (3)

Phosphodiesterase (PDE) (2)

PKA (1)

Potassium Channel (2)

Reactive Oxygen Species (ROS) (4)

Reference Standards (3)

Ribosomal S6 Kinase (RSK) (1)

SOD (1)

STAT (1)

Tau Protein (5)

TNF Receptor (2)

α-synuclein (1)

γ-secretase (2)

By Research Areas:

Cancer (7)

Inflammation/Immunology (7)

Metabolic Disease (7)

Neurological Disease (45)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1462

Chlorzoxazone 3 Publications Verification	Cytochrome P450 Potassium Channel FOXO Amyloid-β	Neurological Disease Inflammation/Immunology
Chlorzoxazone is a SK-type potassium channel activator. Chlorzoxazone modulates FOXO3 phosphorylation and Aβ. Chlorzoxazone enhances immunosuppression, attenuates vasoconstriction, attenuates cognitive deficits, and improves experimental autoimmune encephalomyelitis .

HY-W012722

4-Methyl-2-oxopentanoic acid 1 Publications Verification α-Ketoisocaproic acid	Endogenous Metabolite Autophagy mTOR SOD	Neurological Disease Metabolic Disease
4-Methyl-2-oxopentanoic acid (α-Ketoisocaproic acid) is a metabolite of L-leucine and is involved in energy metabolism. 4-Methyl-2-oxopentanoic acid increases endoplasmic reticulum stress, promotes lipid accumulation in preadipocytes and insulin resistance by impairing mTOR and autophagy signaling pathways. 4-Methyl-2-oxopentanoic acid also causes oxidative damage, leading to cognitive deficits, inhibits α-ketoglutarate dehydrogenase activity, acts as an oxidative phosphorylation uncoupler and metabolic inhibitor. 4-Methyl-2-oxopentanoic acid acts as a nutrient signal and stimulates skeletal muscle protein synthesis. 4-Methyl-2-oxopentanoic acid can be used in the study of maple syrup urine disease .

HY-D0873

HEPPS EPPS	Amyloid-β	Neurological Disease
HEPPS (EPPS) is a buffering agent with the useful pH range from 7.3 ~ 8.7. HEPPS reduces Aβ-aggregate-induced memory deficits and rescues cognitive deficits in mice. EPPS is orally active and penetrates the blood-brain barrier .

HY-N4150

Quercetagitrin 1 Publications Verification Quercetagetin-7-O-glucoside	Phosphatase Tau Protein NF-κB	Neurological Disease Metabolic Disease Inflammation/Immunology
Quercetagitrin (Quercetagetin-7-O-glucoside) is a natural product that can be isolated from the African marigold (Tagetes erecta). Quercetagitrin has anti-inflammatory activity. Quercetagitrin inhibits Tau accumulation. Quercetagitrin can reverse neuroinflammation and cognitive deficits in P301S-Tau transgenic mouse model through inhibiting NF-κB activation. Quercetagitrin is a dual-target inhibitor of PTPN6 (IC₅₀ = 1 μM) and PTPN9 (IC₅₀ = 1.7 μM). Quercetagitrin enhances glucose uptake by mature C2C12 myoblasts. Quercetagitrin can be studied in research for Alzheimer’s disease and type 2 diabetes .

HY-W275295

Perfluorododecanoic acid PFDoA	Reactive Oxygen Species (ROS) Caspase Mitochondrial Metabolism	Neurological Disease Metabolic Disease
Perfluorododecanoic acid (PFDoA) is an orally active, blood-brain barrier-permeable perfluorinated compound. Perfluorododecanoic acid increases Caspase 3 activity, disrupts mitochondrial membrane potential, and elevates ROS levels. Perfluorododecanoic acid induces cognitive deficits. Perfluorododecanoic acid exhibits hepatotoxicity .

HY-15618

MK-7622 M1 receptor modulator	mAChR Calcium Channel	Neurological Disease
MK-7622 (M1 receptor modulator) is an orally active positive allosteric modulator of muscarinic M1 acetylcholine receptors (mAChRs). MK-7622 enhances ACh-induced calcium flux in CHO cells expressing human M1 receptors (EC₅₀ = 21 nM) and shows robust agonist activity in rat M1-expressing CHO cells, increasing intracellular calcium. MK-7622 reverses Scopolamine (HY-N0296)-induced cognitive deficits in rhesus macaques in an object retrieval detour task. MK-7622 can be used for the study of Alzheimer's disease (AD) .

HY-N2255

Crebanine 4 Publications Verification	Akt Apoptosis NF-κB Reactive Oxygen Species (ROS) p38 MAPK ERK Interleukin Related TNF Receptor NO Synthase nAChR Bacterial	Cancer
Crebanine is an isoquinoline-like alkaloid that can be derived from Stephania. Crebanine is an antagonist of the α7-nAChR with an IC₅₀ of 19.1 μM. Crebanine suppresses the proliferation, migration, and invasion of cancer cells, triggers reactive oxygen species (ROS) burst, and promotes apoptosis. Crebanine inhibits the AKT/FoxO3a, NF-κB and MAPK signaling pathways. Crebanine attenuates NOX2 hyperactivation, exhibits antioxidant properties by reducing reactive oxygen species and peroxidation in microglia cells. Crebanine inhibits voltage-dependent Na ⁺ current in guinea-pig ventricular myocytes. Crebanine has high inhibitory activity against gram-positive animal pathogenic bacteria. Crebanine ameliorates ischemia-reperfusion brain damage in middle cerebral artery occlusion and reperfusion (MCAO/R) rats. Crebanine significantly improves Scopolamine (HY-N0296)-induced cognitive deficits in ICR mice. Crebanine can be used for the study of hepatocellular carcinoma (HCC), cerebral ischemia and Alzheimer's disease .

HY-116565

Usmarapride 1 Publications Verification SUVN-D4010	5-HT Receptor	Neurological Disease
Usmarapride (SUVN-D4010) (Example 3)is a potent, selective, orally active and brain penetrant 5-HT₄ receptor partial agonist (EC₅₀=27.5 nM). Usmarapride (SUVN-D4010) can be used for the research of cognitive deficits associated with Alzheimer's disease .

HY-17549

Adrafinil CRL 40028	Adrenergic Receptor	Neurological Disease
Adrafinil (CRL 40028) is an orally active vigilance promoting agent. Adrafinil enhances central noradrenergic transmission, improves spontaneous activity, exploratory behavior, discriminative learning ability and response motivation, but impairs visuospatial working memory. Adrafinil antagonizes Prazosin (HY-B0193)-induced hypoactivity and hypothermia, exerts anticonvulsant effects, and induces sustained enhancement of high-frequency electrocortical activity. Adrafinil can be used for research on decreased alertness and specific cognitive deficits .

HY-162566

REM127	Calcium Channel Amyloid-β	Neurological Disease
REM127 is a small molecule compound capable of modulating calcium homeostasis in cells and possesses neuroprotective effects. REM127 can restore the calcium homeostasis imbalance in cellular models caused by pathological accumulation of tau protein. REM127 can efficiently cross the blood-brain barrier, and it has the potential to rescue synaptic and cognitive deficits in Alzheimer's disease animal models, as well as to slow down the progression of amyloid-beta and tau protein pathologies. REM127 can be used for research in neurodegenerative diseases .

HY-123976

MPT0G211 1 Publications Verification	HDAC	Neurological Disease Cancer
MPT0G211 is a potent, orally active and selective HDAC6 inhibitor (IC₅₀=0.291 nM). MPT0G211 displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 can penetrate the blood-brain barrier. MPT0G211 ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 has anti-metastatic and neuroprotective effects. Anticancer activities .

HY-105670

PHA-543613	nAChR	Neurological Disease
PHA-543613 is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a K_i of 8.8 nM. PHA-543613 displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors . PHA-543613 can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research .

HY-135115

Oleuropein Aglycone 3,4-DHPEA-EA	α-synuclein HDAC Adrenergic Receptor	Inflammation/Immunology
Oleuropein Aglycone (3,4-DHPEA-EA) is a polyphenol and the aglycone form of oleuropein (HY-N0292), formed by enzymatic, acidic or acetylated hydrolysis of oleuropein. Dietary intake of oleuropein Aglycone (50 mg/kg diet) increases the number of neuronal autophagic vesicles, reverses cognitive deficits in the TgCRND8 transgenic mouse model of Alzheimer's disease, and reduces the levels of histone deacetylase 2 (HDAC2) in the cortex and hippocampus. Oleuropein Aglycone increases urinary norepinephrine, interscapular brown adipose tissue epinephrine, and UCP1 protein levels, and reduced plasma leptin levels and total abdominal adipose tissue weight in a rat model of high-fat diet-induced obesity. Oleuropein Aglycone also reduced lung neutrophil infiltration, lipid peroxidation, and IL-1β levels in a mouse model of carrageenan-induced pleurisy.

HY-118342

PQCA 1 Publications Verification	mAChR	Neurological Disease
PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA has an EC₅₀ value of 49 nM and 135 nM on rhesus and human M1 receptor, respectively. PQCA is inactive for other muscarinic receptors. PQCA has potential to reduce the cognitive deficits associated with Alzheimer's disease .

HY-P1173

L803-mts Myristoylated L 803; GSK-3β Inhibitor XIII	GSK-3 Amyloid-β	Neurological Disease
L803-mts (Myristoylated L 803) is a selective and substrate-competitive GSK-3 peptide inhibitor (IC₅₀: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test .

HY-P990001

Anti-Mouse IL-10 Antibody (JES5-2A5) 1 Publications Verification	Interleukin Related	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Anti-Mouse IL-10 Antibody (JES5-2A5) is an anti-mouse IL-10 IgG1 monoclonal antibody. Anti-Mouse IL-10 Antibody (JES5-2A5) restores the anti-tumor activity of IL-6 by blocking the IL-10/SOCS3 axis. Anti-Mouse IL-10 Antibody (JES5-2A5) can reverse microcirculation and cognitive deficits. Anti-Mouse IL-10 Antibody (JES5-2A5) can be used for researches on cancer and metabolic disease such as osteosarcoma and type 1 diabetes mellitus (T1DM) .

HY-118956

Adrogolide hydrochloride ABT-431 hydrochloride; DAS-431 hydrochloride	Dopamine Receptor	Neurological Disease
Adrogolide hydrochloride (ABT-431 hydrochloride) is a chemically stable prodrug that can convert to the dopamine D1 receptor agonist A-86929. Adrogolide hydrochloride ameliorates the MPTP (HY-15608)-induced Parkinson's Disease in marmoset model, reduces the dyskinesias tendency. Adrogolide hydrochloride reverses Risperidone (HY-11018)-induced cognitive deficits in monkey .

HY-115383

Roflupram 1 Publications Verification	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology
Roflupram is a selective, orally active and brain-penetrant PDE4 inhibitor, with an IC₅₀ of 26.2 nM for core catalytic domains of human PDE4. Roflupram can reverse cognitive deficits and reduce the production of pro-inflammatory factors .

HY-148325

α7 Nicotinic receptor agonist-1	nAChR	Neurological Disease
α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .

HY-149651

GPR139 agonist-2	GPR139	Neurological Disease
GPR139 agonist-2 (compound 20a) is a potent GPR139 agonist with an EC₅₀ of 24.7 nM. GPR139 agonist-2 rescues the social interaction deficits and alleviates cognitive deficits in murine schizophrenia models. GPR139 agonist-2 has the potential for antischizophrenia drug research .

HY-105670B

PHA-543613 dihydrochloride	nAChR	Neurological Disease
PHA-543613 dihydrochloride is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a K_i value of 8.8 nM. PHA-543613 dihydrochloride displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors . PHA-543613 dihydrochloride can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research .

HY-N10408

Tripchlorolide	Apoptosis Autophagy	Neurological Disease Cancer
Tripchlorolide is a neuroprotective agent that can be found in Tripterygium wilfordii. Tripchlorolide prevents tumor growth by inducing apoptosis and autophagy. Tripchlorolide improves cognitive deficits in Alzheimer's disease .

HY-116565A

Usmarapride free base 1 Publications Verification SUVN-D4010 free base	5-HT Receptor	Neurological Disease
Usmarapride (SUVN-D4010) free base is a potent, selective, orally active and brain penetrant 5-HT₄ receptor partial agonist (EC₅₀=44 nM). Usmarapride (SUVN-D4010) free base can be used for the research of cognitive deficits associated with Alzheimer's disease .

HY-121041

GEBR-7b	Phosphodiesterase (PDE)	Neurological Disease
GEBR-7b is a selective PDE4D inhibitor with an IC₅₀ of 0.67 μM. GEBR-7b increases hippocampal cAMP and does not influence Aβ levels in rodents. GEBR-7b also improves spatial and can be used for the study of cognitive deficits .

HY-123928

Contilisant	Reactive Oxygen Species (ROS) Histamine Receptor Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease Metabolic Disease
Contilisant is a permeable antioxidant and neuroprotectant agent. Contilisant exhibits high nM affinity at H3R. Contilisant inhibits monoamine oxidases and cholinesterases. Contilisant has a binding affinity of 65.23 nM towards hS1R. Contilisant can significantly restore cognitive deficit induced by Aβ_1-42 in the radial maze assay of Alzheimer’s animal model .

HY-165341

SCR1693	Amyloid-β Cholinesterase (ChE) Calcium Channel GSK-3 Tau Protein Phosphatase Akt PKA	Neurological Disease Metabolic Disease
SCR1693 is a selective, reversible, orally active and noncompetitive inhibitor of AChE (IC₅₀ = 0.68 μM) as well as a calcium channel blocker. SCR1693 reduces tau phosphorylation levels, and inhibits the generation and release of Aβ. SCR1693 restores insulin signaling and improves cognitive deficits. SCR1693 can be used for the study of Alzheimer's disease, especially which complicated with type 2 diabetes mellitus .

HY-179363

BChE-IN-46	Cholinesterase (ChE) COX	Neurological Disease
BChE-IN-46 is a selective and brain-penetrant BChE inhibitor (eqBChE IC₅₀ = 7.44 × 10 ⁻⁵ μM, SI > 270,000; hBChE, IC₅₀ = 1.48 × 10 ⁻³ μM). BChE-IN-46 has COX-2 inhibitory activity (IC₅₀ = 0.11 μM). BChE-IN-46 exhibits neuroprotective effects, enhances acetylcholine levels, and alleviates cognitive deficits, anxiety, and learning/memory impairments. BChE-IN-46 can be used for the development of anti-Alzheimer's disease drugs .

HY-14565

Pozanicline ABT-089	nAChR	Neurological Disease
Pozanicline (ABT-089) selectively activate neuronal nicotinic acetylcholine receptor (nAChR) subtypes, is a novel cholinergic agent that is a partial agonist at α4β2* nAChRs (K_i=16 nM) and shows high selectivity for α6β2* and α4α5β2 nAChR subtypes, the binding affinity (K_i, rat) for Pozanicline to [ ³H] cytisine sites is 16.7 nM. Pozanicline reverses nicotine withdrawal-induced cognitive deficits, may be an effective component of novel therapeutic strategies for nicotine addiction .

HY-171807

TC-2559 free base	nAChR STAT	Neurological Disease Inflammation/Immunology
TC-2559 free base is a α4β2 nicotinic acetylcholine receptor (nAChR) agonists with an EC₅₀ of 0.18 μM. TC-2559 free base shows much weaker potencies on the group of b4-containing nAChR subtypes, α2β4, α4β4 and α3β4 receptors, with EC₅₀s in the range of 10-30 µM. TC-2559 free base can increase the discharge of dopamine cells in the ventral tegmental area (VTA) of rats in vitro, enhancing the excitability and aggressive behavior of VTA dopamine neurons. TC-2559 free base inhibits STAT3 to exert anti-inflammatory properties and relieves mice mechanical allodynia and improve rats cognitive deficits. TC-2559 free base can be used for the study of nerve pain .

HY-168264

MC1	NOD-like Receptor (NLR)	Neurological Disease
MC1 is a potent NLRP3 inhibitor with a K_D value of 19.3 nM. MC1 shows no cytotoxicity. MC1 ameliorates cognitive deficits without eliciting adverse effects and shows an absence of hepatotoxicity. MC1 has the potential for the research of Alzheimer's disease (AD) .

HY-162339

BChE-IN-30	Cholinesterase (ChE)	Neurological Disease
BChE-IN-30 (compound (R)-37a) is a BChE inhibitor (IC₅₀: 5 nM) with anti-inflammatory activity and low toxicity. BChE-IN-30 can improve cognitive deficits induced by scopolamine and Aβ1-42 peptide and can be used in the study of late-stage AD .

HY-147720

γ-Secretase modulator 11	γ-secretase	Neurological Disease
γ-Secretase modulator 11 (1o) showed high potency in vitro and brain exposure, inducing brain a β 42 levels were significantly reduced and showed undetectable inhibition of cytochrome P450 enzymes. In addition, compound 1o showed excellent anti cognitive deficit effect in AD model mice.

HY-155116

5-HT6 agonist 1	5-HT Receptor	Neurological Disease
5-HT6 agonist 1 (Compound 19) is a 5-HT6 agonist (K_i: 5 nM). 5-HT6 agonist 1 has antidepressant-like properties, and improves cognitive deficits. 5-HT6 agonist 1 also inhibits platelet aggregation. 5-HT6 agonist 1 has high metabolic stability .

HY-147720A

γ-Secretase modulator 11 hydrochloride	γ-secretase	Neurological Disease
γ-Secretase modulator 11 hydrochloride (compound 1o) is a potent and orally active γ-secretase modulator with an IC₅₀ of 0.029 µM. γ-Secretase modulator 11 hydrochloride induces a robust reduction in brain Aβ42 levels. γ-Secretase modulator 11 hydrochloride rescues cognitive deficits exhibited by AD model mice. γ-Secretase modulator 11 hydrochloride has the potential for the research of alzheimer's disease .

HY-118575

DR-4004	5-HT Receptor	Neurological Disease
DR-4004 is a 5-HT₇ receptor antagonist that attenuates the decreased level of performance produced by mCPP and the performance levels after p-chloroamphetamine (PCA) lesion of the 5-HT system. DR-4004 also reverses amnesia induced by Scopolamine (HY-N0296) and Dizocilpine (HY-15084B). DR-4004 is promising for research of schizophrenia, cognitive deficits and atypical antipsychotic agents .

HY-123976A

MPT0G211 mesylate	HDAC	Neurological Disease Cancer
MPT0G211 mesylate is a potent, orally active and selective HDAC6 inhibitor (IC₅₀=0.291 nM). MPT0G211 mesylate displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 mesylate can penetrate the blood-brain barrier. MPT0G211 mesylate ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 mesylate has anti-metastatic and neuroprotective effects. Anticancer activities .

HY-171472

A-86929	Dopamine Receptor	Neurological Disease
A-86929 is a highly potent and selective dopamine D₁ receptor agonist with a pK_i value of 7.3. In the 6-OHDA (HY-B1081)-induced unilateral nigrostriatal lesion rat model, A-86929 significantly induces rotational behavior. It also improves motor function in the MPTP (HY-15608)-induced Parkinson's disease marmoset model. Additionally, A-86929 demonstrates potential therapeutic value in reducing cocaine-seeking behavior in rats and reversing Haloperidol (HY-14538)-induced cognitive deficits in rhesus monkeys. A-86929 can be used for research in neurological disorders .

HY-107650

Milameline hydrochloride CI 979 hydrochloride; RU 35926 hydrochloride	mAChR	Neurological Disease
Milameline (CI 979; RU35926) hydrochloride is a nonselective, partical and orally active muscarinic receptor agonist that improves cognition. Milameline hydrochloride has equal affinity for different subtypes of human muscarinic receptors with IC₅₀ of 1.3 µM for M1-, 1.1 µM for M2-, 1.5 µM for M3-, and 1.9 µM for M4-muscarinic receptors. Milameline hydrochloride has a higher affinity for sites [ ³H]CMD (IC₅₀ = 20 nM), than [ ³H]QNB, (IC₅₀ = 3059 nM). Milameline hydrochloride produces both central and peripheral cholinergic effects and reverses the cognitive deficits induced by Scopolamine (HY-N0296). Milameline hydrochloride can be used for the study of Alzheimer’s Disease .

HY-135460

Milameline CI-979; RU35926	mAChR	Neurological Disease
Milameline (CI-979; RU35926) is a nonselective, partical and orally active muscarinic receptor agonist that improves cognition. Milameline has equal affinity for different subtypes of human muscarinic receptors with IC₅₀ of 1.3 µM for M1-, 1.1 µM for M2-, 1.5 µM for M3-, and 1.9 µM for M4-muscarinic receptors. Milameline has a higher affinity for sites [ ³H]CMD (IC₅₀ = 20 nM), than [ ³H]QNB, (IC₅₀ = 3059 nM). Milameline produces both central and peripheral cholinergic effects and reverses the cognitive deficits induced by Scopolamine (HY-N0296). Milameline can be used for the study of Alzheimer’s Disease .

HY-N4150R

Quercetagitrin (Standard) Quercetagetin-7-O-glucoside (Standard)	Reference Standards Phosphatase Tau Protein NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Quercetagitrin (Standard) is the analytical standard of Quercetagitrin. This product is intended for research and analytical applications. Quercetagitrin (Quercetagetin-7-O-glucoside) is a natural product that can be isolated from the African marigold (Tagetes erecta). Quercetagitrin has anti-inflammatory activity. Quercetagitrin inhibits Tau accumulation. Quercetagitrin can reverse neuroinflammation and cognitive deficits in P301S-Tau transgenic mouse model through inhibiting NF-κB activation. Quercetagitrin is a dual-target inhibitor of PTPN6 (IC₅₀ = 1 μM) and PTPN9 (IC₅₀ = 1.7 μM). Quercetagitrin enhances glucose uptake by mature C2C12 myoblasts. Quercetagitrin can be studied in research for Alzheimer’s disease and type 2 diabetes .

HY-123661

MIPS1455	Endogenous Metabolite	Neurological Disease
MIPS1455 is a light-activated M1 muscarinic acetylcholine receptor ligand with irreversible binding activity to the allosteric site of the receptor. MIPS1455 is a drug target under investigation for the suppression of cognitive deficits and may become a valuable molecular tool for further investigation of allosteric interactions of the receptor .

HY-179723

GSK3β-IN-4	GSK-3 Tau Protein	Neurological Disease
GSK3β-IN-4 is a selective, potent, orally active and brain-penetrant ATP-competitive GSK3β inhibitor with an IC₅₀ of 0.37 nM. GSK3β-IN-4 shows an IC₅₀ of 2.75 nM and SI of 7.4 for GSK3α. GSK3β-IN-4 reduces tau phosphorylation at Ser396 by inhibiting GSK3β and imoroves cognitive deficits in Alzheimer's disease models. GSK3β-IN-4 can be used for the research of Alzheimer's disease .

HY-103100R

SB-699551 (Standard)	Reference Standards 5-HT Receptor Epigenetic Reader Domain Akt Ribosomal S6 Kinase (RSK) FOXO	Neurological Disease Cancer
SB-699551 (Standard) is the analytical standard of SB-699551 (HY-103100). This product is intended for research and analytical applications. SB-699551 is a potent and selective 5-HT5A antagonist with a K_i value of 5.1 μM. SB-699551 increases the phosphorylation levels of CREB and ATF1, and decreases the phosphorylation levels of AKT, PRAS40, P70S6K, FOXO1, and S6RP. SB-699551 improves drug-induced cognitive deficits. SB-699551 improves social withdrawal and forgetfulness. SB-699551 inhibits breast cancer.

HY-105670R

PHA-543613 (Standard)	Reference Standards nAChR	Neurological Disease
PHA-543613 (Standard) is the analytical standard of PHA-543613 (HY-105670). This product is intended for research and analytical applications. PHA-543613 is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a K_i of 8.8 nM. PHA-543613 displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors . PHA-543613 can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research .

HY-183280

17β-HSD10/CDK5-IN-1	17β-HSD CDK Amyloid-β Tau Protein Reactive Oxygen Species (ROS)	Neurological Disease
17β-HSD10/CDK5-IN-1 is a poent dual 17β-HSD10 and CDK5 inhibitor with IC₅₀s of 2.44 and 0.26 μM for 17β-HSD10 and CDK5, respectively. 17β-HSD10/CDK5-IN-1 reduces ROS accumulation, attenuates pathological Tau phosphorylation, reduces Aβ plaque deposition, and ameliorates cognitive deficits in Alzheimer's mice. 17β-HSD10/CDK5-IN-1 can be used for the research of Alzheimer's disease .

HY-107650A

Milameline hydroiodide CI 979 hydroiodide; RU 35926 hydroiodide	mAChR	Neurological Disease
Milameline (CI 979; RU35926) hydroiodide is a nonselective, partical and orally active muscarinic receptor agonist that improves cognition. Milameline hydroiodide has equal affinity for different subtypes of human muscarinic receptors with IC₅₀ of 1.3 µM for M1-, 1.1 µM for M2-, 1.5 µM for M3-, and 1.9 µM for M4-muscarinic receptors. Milameline hydroiodide has a higher affinity for sites [ ³H]CMD (IC₅₀ = 20 nM), than [ ³H]QNB, (IC₅₀ = 3059 nM). Milameline hydroiodide produces both central and peripheral cholinergic effects and reverses the cognitive deficits induced by Scopolamine (HY-N0296). Milameline hydroiodide can be used for the study of Alzheimer’s Disease .

HY-179724A

PZ-1657 hydrochloride	5-HT Receptor Dopamine Receptor MMP Potassium Channel	Neurological Disease
PZ-1657 hydrochloride (Compound 57) is a potent, selective and orally active 5-HT7 receptor inverse agonist with a K_i of 5 nM. PZ-1657 hydrochloride can inhibit the constitutive cAMP production mediated by the Gs signaling pathway (EC₅₀ = 2.93 nM). PZ-1657 hydrochloride can significantly reduce the MMP-9 activity mediated by 5-HT7 receptors in the hippocampus of mice, and the effect is comparable to that of SB-269970 (HY-15370). PZ-1657 hydrochloride can reverse the cognitive deficits observed in the rat novel object recognition test induced by Phencyclidine without affecting the animals' spontaneous activities. PZ-1657 hydrochloride can be used for the research of emotional disorders, such as depression and bipolar disorder .

HY-182707

JWX-A0108	nAChR Interleukin Related TNF Receptor NF-κB	Neurological Disease
JWX-A0108 is a selective human α7 nAChR positive allosteric modulator with an EC₅₀ of 4.35 μM. JWX-A0108 potentiates α7 nAChR currents only in the presence of acetylcholine, with no direct activating effect or alteration of desensitization. JWX-A0108 enhances hippocampal GABAergic synaptic transmission by increasing spontaneous inhibitory postsynaptic currents. JWX-A0108 reduces the brain expression levels of IL-1β, TNF-α, and IL-6 by blocking the NF-κB signaling pathway, and reduces microglial activation by downregulating Iba1. JWX-A0108 effectively improves cognitive deficits, neuroinflammation, and hippocampal neuronal damage in mouse models of schizophrenia and Alzheimer's disease. JWX-A0108 can be used for research related to schizophrenia and Alzheimer's disease .

Cat. No.	Product Name	Target	Research Area